Investigating how lactate transporters affect lung scarring
Role of lactate transporters in pulmonary fibrosis
['FUNDING_R01'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-11109558
This study is looking at how certain proteins that help move lactate in the body affect the cells that cause scarring in the lungs of people with idiopathic pulmonary fibrosis (IPF), and by blocking these proteins, the researchers hope to find a way to reduce lung scarring and improve health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11109558 on ClinicalTrials.gov |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by excessive scarring. The study aims to understand how lactate transporters influence the differentiation of myofibroblasts, which are key cells involved in lung fibrosis. By inhibiting these transporters, the researchers hope to prevent myofibroblast differentiation and reduce lung scarring. The approach includes both laboratory experiments and animal models to explore the metabolic changes associated with lactate transporter inhibition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or those at risk of developing this condition.
Not a fit: Patients with other forms of lung disease or those without pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antifibrotic therapies that significantly improve outcomes for patients with pulmonary fibrosis.
How similar studies have performed: Previous research has shown promising results with metabolic approaches in treating fibrosis, suggesting potential for success in this novel investigation.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OLDHAM, WILLIAM MICHAEL — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: OLDHAM, WILLIAM MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.